Head of International Markets & Business Affairs, Member of the Management BoardContact us
In spring 2018 the US animal health manufacturer Zoetis moved its Swiss business operations to the Basel region. The relocation has now been completed and all employees have taken up their workplaces. Of the 17 staff, 12 are based in canton Jura, while five work for the sales team.
Pfizer spun off its animal health division at the end of 2012 and listed it on the stock exchange as Zoetis in 2013. Five years later the time came for Zoetis to distance itself from Pfizer geographically as well. The Basel region was right at the top of its list in view of its outstanding talent pool in the life science sector. Most employees relocated with the company while other specialists were easily recruited.
Zoetis turned to the Jura regional development agency in 2017. Given the attractive framework conditions and excellent cooperation with the cantonal authorities, Zoetis’ decision was a quick one. “We wanted to be close to a city with good links to the railway network and an airport,” explained Laurent Monnerat, Zoetis Senior Vice President Germany, Central and Eastern Europe. The company’s Swiss operations will be managed from the Delémont headquarters in Jura and international projects will also be coordinated from there. A further benefit of the location is that the offices are situated within walking distance of the railway station, making them easily accessible for commuters. The EuroAirport Basel, which customers and partners abroad fly into, is also nearby.
Zoetis produces around 300 animal health products which are marketed in just under 100 countries. The company employs about 9,000 staff worldwide and posted revenue of USD 5.3 billion in 2017. The company’s Swiss headquarters were previously located in Zurich. The company invests between CHF 300 and 400 million in research and development worldwide. Zoetis is also well positioned in the field of diagnostics thanks to acquisitions.